An Opiate Blocker Also Blocked THC Effects in Rats, Suggesting Shared Brain Pathways
An irreversible opiate antagonist inhibited THC-induced pain relief, body temperature reduction, tolerance, and physical dependence in rats, suggesting cannabis and opiates share some overlapping brain mechanisms.
Quick Facts
What This Study Found
Researchers administered chlornaltrexamine (beta-CNA), a long-acting irreversible opiate receptor blocker, to rats before giving them THC. The opiate blocker inhibited several key THC effects: pain relief (analgesia), body temperature reduction (hypothermia), the development of tolerance to hypothermia, and the development of physical dependence.
These results suggested that some of THC's effects in the brain are mediated through opioid-related mechanisms, meaning cannabis and opiates share common features in how they interact with the central nervous system.
Key Numbers
Beta-CNA inhibited four measured THC effects: analgesia, hypothermia, hypothermia tolerance, and physical dependence.
How They Did This
Animal study in rats using chlornaltrexamine (beta-CNA), a selective irreversible opiate antagonist, administered before THC. Measured analgesia, hypothermia, hypothermia tolerance, and physical dependence.
Why This Research Matters
This study provided early pharmacological evidence for cross-talk between the cannabinoid and opioid systems in the brain. This connection has since become a major area of research, with implications for pain management, addiction treatment, and understanding why cannabis and opioids can sometimes substitute for each other.
The Bigger Picture
The cannabinoid-opioid interaction documented here was foundational. Decades of subsequent research confirmed extensive overlap between these systems, leading to investigations of whether cannabis might reduce opioid requirements for pain management, a question with major public health implications during the opioid crisis.
What This Study Doesn't Tell Us
Animal study in rats; results may not translate directly to humans. Chlornaltrexamine is not perfectly selective, so some effects could involve non-opioid mechanisms. The study did not identify which specific opioid receptor subtypes were involved.
Questions This Raises
- ?Which specific opioid receptors mediate THC's effects?
- ?Does this cross-talk exist in humans at clinically relevant doses?
- ?Could this interaction be leveraged therapeutically to reduce opioid requirements?
Trust & Context
- Key Stat:
- An opiate blocker inhibited four distinct THC effects in rats
- Evidence Grade:
- An animal pharmacology study providing mechanistic insight. Valuable for understanding biological pathways but cannot be directly applied to human clinical use.
- Study Age:
- Published in 1981. The endocannabinoid system was not discovered until 1988-1992, so the full picture of cannabinoid-opioid interaction was not yet understood.
- Original Title:
- Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats.
- Published In:
- European journal of pharmacology, 70(2), 219-24 (1981)
- Authors:
- Tulunay, F C, Ayhan, I H, Portoghese, P S, Takemori, A E
- Database ID:
- RTHC-00023
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does this mean cannabis works like an opiate?
Not exactly. It means some of THC's effects appear to involve opioid-related pathways in the brain, but cannabis and opiates are distinct drug classes with different primary mechanisms.
Is this relevant to using cannabis for pain?
Yes. The overlap between cannabinoid and opioid systems is now a major area of research, particularly regarding whether cannabis can reduce the amount of opioids needed for pain management.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- thc-patches-suppositories-topicals-explained
- thc-and-muscle-relaxers-combining
- cannabis-and-migraines-prevention-treatment
- cannabis-and-endometriosis-thc-pain
- cannabis-and-menstrual-cramps-period-pain
Cite This Study
https://rethinkthc.com/research/RTHC-00023APA
Tulunay, F C; Ayhan, I H; Portoghese, P S; Takemori, A E. (1981). Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats.. European journal of pharmacology, 70(2), 219-24.
MLA
Tulunay, F C, et al. "Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats.." European journal of pharmacology, 1981.
RethinkTHC
RethinkTHC Research Database. "Antagonism by chlornaltrexamine of some effects of delta 9-t..." RTHC-00023. Retrieved from https://rethinkthc.com/research/tulunay-1981-antagonism-by-chlornaltrexamine-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.